Equities Analysts Offer Predictions for NMRA FY2029 Earnings

Neumora Therapeutics, Inc. (NASDAQ:NMRA) – Equities researchers at William Blair issued their FY2029 earnings per share estimates for shares of Neumora Therapeutics in a research report issued on Thursday, January 2nd. William Blair analyst M. Minter anticipates that the company will post earnings per share of $1.47 for the year. The consensus estimate for Neumora Therapeutics’ current full-year earnings is ($1.61) per share.

Neumora Therapeutics (NASDAQ:NMRA) last issued its earnings results on Tuesday, November 12th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.06). During the same period in the previous year, the company earned ($1.14) earnings per share.

Several other research analysts have also issued reports on NMRA. Bank of America dropped their price target on shares of Neumora Therapeutics from $22.00 to $7.00 and set a “buy” rating for the company in a research report on Monday. JPMorgan Chase & Co. lowered Neumora Therapeutics from an “overweight” rating to a “neutral” rating and dropped their price objective for the stock from $18.00 to $15.00 in a research note on Tuesday, November 5th. Needham & Company LLC reaffirmed a “buy” rating and issued a $23.00 target price on shares of Neumora Therapeutics in a report on Thursday, January 2nd. HC Wainwright reissued a “buy” rating and set a $30.00 price target on shares of Neumora Therapeutics in a report on Friday, January 3rd. Finally, Royal Bank of Canada cut shares of Neumora Therapeutics from an “outperform” rating to a “sector perform” rating and decreased their price objective for the stock from $29.00 to $4.00 in a research note on Thursday, January 2nd. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, Neumora Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $16.50.

Neumora Therapeutics Stock Performance

NASDAQ:NMRA opened at $2.58 on Monday. The company has a 50-day moving average of $10.10 and a 200-day moving average of $11.42. Neumora Therapeutics has a 52 week low of $1.83 and a 52 week high of $21.00. The company has a market capitalization of $416.83 million, a price-to-earnings ratio of -1.38 and a beta of 2.71.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Amalgamated Bank raised its stake in shares of Neumora Therapeutics by 472.8% during the second quarter. Amalgamated Bank now owns 2,910 shares of the company’s stock worth $29,000 after buying an additional 2,402 shares during the last quarter. Quarry LP bought a new stake in Neumora Therapeutics in the second quarter valued at about $98,000. Intech Investment Management LLC acquired a new position in Neumora Therapeutics in the third quarter valued at about $175,000. Ballentine Partners LLC acquired a new position in shares of Neumora Therapeutics during the 3rd quarter worth about $178,000. Finally, SkyOak Wealth LLC bought a new stake in shares of Neumora Therapeutics in the 2nd quarter valued at about $147,000. 47.65% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, Director Matthew K. Fust sold 14,049 shares of the business’s stock in a transaction on Friday, October 18th. The stock was sold at an average price of $17.03, for a total transaction of $239,254.47. Following the completion of the sale, the director now owns 20,100 shares in the company, valued at $342,303. The trade was a 41.14 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 26.40% of the company’s stock.

Neumora Therapeutics Company Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.